117 related articles for article (PubMed ID: 19238167)
1. Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy.
Furihata T; Satoh N; Ohishi T; Ugajin M; Kameyama Y; Morimoto K; Matsumoto S; Yamashita K; Kobayashi K; Chiba K
Pharmacogenomics J; 2009 Jun; 9(3):185-93. PubMed ID: 19238167
[TBL] [Abstract][Full Text] [Related]
2. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y
Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545
[TBL] [Abstract][Full Text] [Related]
3. Construction of HEK293 cells stably expressing wild-type organic anion transporting polypeptide 1B1 (OATP1B1*1a) and variant OATP1B1*1b and OATP1B1*15.
Chen M; Qu BX; Chen XL; Hu HH; Jiang HD; Yu LS; Zhou Q; Zeng S
Pharmazie; 2016 Jun; 71(6):337-9. PubMed ID: 27455553
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
Kameyama Y; Yamashita K; Kobayashi K; Hosokawa M; Chiba K
Pharmacogenet Genomics; 2005 Jul; 15(7):513-22. PubMed ID: 15970799
[TBL] [Abstract][Full Text] [Related]
5. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
Kivistö KT; Niemi M
Pharm Res; 2007 Feb; 24(2):239-47. PubMed ID: 17177112
[TBL] [Abstract][Full Text] [Related]
6. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.
Aquilante CL; Kiser JJ; Anderson PL; Christians U; Kosmiski LA; Daily EB; Hoffman KL; Hopley CW; Predhomme JA; Schniedewind B; Sidhom MS
J Clin Pharmacol; 2012 Nov; 52(11):1725-38. PubMed ID: 22174437
[TBL] [Abstract][Full Text] [Related]
7. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.
Deng JW; Song IS; Shin HJ; Yeo CW; Cho DY; Shon JH; Shin JG
Pharmacogenet Genomics; 2008 May; 18(5):424-33. PubMed ID: 18408565
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors.
Choi MK; Shin HJ; Choi YL; Deng JW; Shin JG; Song IS
Xenobiotica; 2011 Jan; 41(1):24-34. PubMed ID: 20946088
[TBL] [Abstract][Full Text] [Related]
9. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
Niemi M; Pasanen MK; Neuvonen PJ
Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
[TBL] [Abstract][Full Text] [Related]
10. Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing.
Rohrbacher M; Kirchhof A; Skarke C; Geisslinger G; Lötsch J
Pharmacogenomics; 2006 Mar; 7(2):167-76. PubMed ID: 16515396
[TBL] [Abstract][Full Text] [Related]
11. Analysis of amino acid residues in the predicted transmembrane pore influencing transport kinetics of the hepatic drug transporter organic anion transporting polypeptide 1B1 (OATP1B1).
Gruetz M; Sticht H; Glaeser H; Fromm MF; König J
Biochim Biophys Acta; 2016 Nov; 1858(11):2894-2902. PubMed ID: 27594653
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction between genetics and disease on pravastatin disposition.
Clarke JD; Hardwick RN; Lake AD; Lickteig AJ; Goedken MJ; Klaassen CD; Cherrington NJ
J Hepatol; 2014 Jul; 61(1):139-47. PubMed ID: 24613363
[TBL] [Abstract][Full Text] [Related]
13. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics.
Katz DA; Carr R; Grimm DR; Xiong H; Holley-Shanks R; Mueller T; Leake B; Wang Q; Han L; Wang PG; Edeki T; Sahelijo L; Doan T; Allen A; Spear BB; Kim RB
Clin Pharmacol Ther; 2006 Mar; 79(3):186-96. PubMed ID: 16513443
[TBL] [Abstract][Full Text] [Related]
14. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics.
Mwinyi J; Johne A; Bauer S; Roots I; Gerloff T
Clin Pharmacol Ther; 2004 May; 75(5):415-21. PubMed ID: 15116054
[TBL] [Abstract][Full Text] [Related]
15. SLCO1B1 variants and statin-induced myopathy.
Vladutiu GD; Isackson PJ
N Engl J Med; 2009 Jan; 360(3):304. PubMed ID: 19144951
[No Abstract] [Full Text] [Related]
16. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Noé J; Portmann R; Brun ME; Funk C
Drug Metab Dispos; 2007 Aug; 35(8):1308-14. PubMed ID: 17470528
[TBL] [Abstract][Full Text] [Related]
17. Drug-drug interaction between pitavastatin and various drugs via OATP1B1.
Hirano M; Maeda K; Shitara Y; Sugiyama Y
Drug Metab Dispos; 2006 Jul; 34(7):1229-36. PubMed ID: 16595711
[TBL] [Abstract][Full Text] [Related]
18. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy.
Morimoto K; Oishi T; Ueda S; Ueda M; Hosokawa M; Chiba K
Drug Metab Pharmacokinet; 2004 Dec; 19(6):453-5. PubMed ID: 15681900
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1).
van de Steeg E; van der Kruijssen CM; Wagenaar E; Burggraaff JE; Mesman E; Kenworthy KE; Schinkel AH
Drug Metab Dispos; 2009 Feb; 37(2):277-81. PubMed ID: 19022939
[TBL] [Abstract][Full Text] [Related]
20. Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>C.
Seithel A; Klein K; Zanger UM; Fromm MF; König J
Mol Genet Genomics; 2008 Feb; 279(2):149-57. PubMed ID: 17989996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
